RT Journal Article
SR Electronic
T1 Analysis of host immunological response of adenovirus-based COVID-19 vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.24.21259460
DO 10.1101/2021.06.24.21259460
A1 Farhang-Sardroodi, Suzan
A1 Korosec, Chapin
A1 Gholami, Samaneh
A1 Craig, Morgan
A1 Moyles, Iain R
A1 Ghaemi, Mohammad Sajjad
A1 Ooi, Hsu Kiang
A1 Heffernan, Jane M
YR 2021
UL http://medrxiv.org/content/early/2021/06/25/2021.06.24.21259460.abstract
AB During the SARS-CoV-2 global pandemic, several vaccines, including mRNA and ade-novirus vector approaches, have received emergency or full approval. However, supply chain logistics have hampered global vaccine delivery, which is impacting mass vaccination strategies. Recent studies have identified different strategies for vaccine dose administration so that supply constraints issues are diminished. These include increasing the time between consecutive doses in a two-dose vaccine regimen and reducing the dosage of the second dose. We consider both of these strategies in a mathematical modeling study of a non-replicating viral vector adenovirus vaccine in this work. We investigate the impact of different prime-boost strategies by quantifying their effects on immunological outcomes based on simple ordinary differential equations. The boost dose is administered either at a standard dose (SD) of 1000 or at a low dose (LD) of 500 or 250 vaccine particles. Simulated Second dose fractionation highlights previously shown dose-dependent features of the immune mechanism. In agreement with clinical characteristics of 175 COVID-19 recovered patients, the model predictions for either SD/SD or SD/LD regimens mainly show that by stretching the prime-boost interval until 18 or 20 weeks, the minimum promoted antibody (Nab) response is comparable with the neutralizing antibody level of COVID-19 recovered patients. The minimum stimulated antibody in SD/SD regimen is identical with the high level of clinical trial data. It is at the same range of the medium-high level of Nab in SD/LD, where the second dose is half or quarter of the standard dose.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is supported by NSERC Discovery Grant, CIHR-Fields COVID Immunity Task Force, NRC Pandemic Response Challenge Program Grant No. PR016-1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Authors: Suzan Farhang-Sardroodi, Chapin Korosec, Samaneh Gholami, Morgan Craig, Iain R Moyles, Mohammad Sajjad Ghaemi, Hsu Kiang Ooi, and Jane M HeffernanAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in the manuscript is from the literature and is provided inside the paper.